Compare QSR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSR | BIIB |
|---|---|---|
| Founded | 1954 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 24.2B |
| IPO Year | 2006 | 1991 |
| Metric | QSR | BIIB |
|---|---|---|
| Price | $67.90 | $177.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 22 |
| Target Price | $73.94 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.81 | ★ 10.97 |
| Revenue | $9,264,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $12.57 | $3.58 |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $24.32 | ★ $16.04 |
| Revenue Growth | ★ 16.82 | 4.77 |
| 52 Week Low | $58.71 | $110.04 |
| 52 Week High | $73.70 | $185.17 |
| Indicator | QSR | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 57.95 |
| Support Level | $68.80 | $175.00 |
| Resistance Level | $70.05 | $178.46 |
| Average True Range (ATR) | 0.91 | 3.50 |
| MACD | -0.37 | -0.44 |
| Stochastic Oscillator | 21.03 | 86.16 |
Restaurant Brands generates about $44 billion in system sales across more than 32,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,082 stores), Tim Hortons (4,539), Popeyes (3,520), and Firehouse Subs (1,345), concentrated in the US and Canada, with these brands also comprising 15,639 franchised international locations as of year-end 2024. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).